Navigating the CMS 14-Day Rule in Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

October 16, 2015

Pembrolizumab vs. Ipilimumab

Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.

October 1, 2014

The Changing Role of Pharmacists

Hear Atheer Kaddis describe how the role of the pharmacist is changing in hematology and oncology.Supported through funding from Incyte